Canady Biotechnology

Canady Biotechnology is a clinical-stage biotechnology company focused on the development of Cold Atmospheric Plasma (CAP) for the selective treatment of cancer. The company's core technology, the Canady Helios Cold Plasma System, is designed to selectively target and kill cancer cells while sparing healthy tissue by inducing apoptosis and inhibiting tumor cell proliferation. This technology is integrated into surgical workflows to treat the surgical margins after tumor resection, aiming to reduce recurrence. Canady Biotechnology operates as part of the US Medical Innovations family of companies, leveraging advanced electrosurgical platforms to deliver its proprietary plasma therapies.